Physician profile
Mark A Chung
NPI 1841316833
$17,438.41
in general payments reported to CMS, 2019-2025
11 companies · $2,612 in 2025
The $2,612 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,323 · 2020: $852 · 2021: $1,651 · 2022: $2,575 · 2023: $3,071 · 2024: $2,355 · 2025: $2,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,985 · Entertainment: $53.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,985.18 |
| Entertainment | $53.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,648.78 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Coopervision INC. | $4,416.57 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $2,632.05 | 2022-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Photrexa Viscous and Photrexa |
| Johnson & Johnson Vision Care, INC. | $2,347.61 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,215.99 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $671.75 | 2019-2022 | |
| Allergan, INC. | $161.44 | 2022 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Staar Surgical Company | $97.58 | 2019 | |
| Abbvie INC. | $68.56 | 2022 | |
| Optos, INC. | $53.08 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.